Status:
COMPLETED
PK of Lidocaine/Tetracaine and PD Derived From a New Topical Formulation for Treatment of Neuropathic Pain.
Lead Sponsor:
Pontificia Universidad Catolica de Chile
Conditions:
Neuralgia
Neuropathic Pain
Eligibility:
All Genders
50+ years
Brief Summary
Post-herpetic neuralgia (PHN) is the most frequent complications related to herpes zoster, and can persist for months or even years, and require extensive treatment. For this purpose, pharmacological ...
Detailed Description
The International Association for the Study of Pain (IASP), defines neuropathic pain as "pain caused by injury or pathology of the somatosensory system", which is usually moderate to severe intensity,...
Eligibility Criteria
Inclusion
- Trigeminal neuralgia
- Postherpetic neuralgia
- Diabetic neuropathy
- Chronic postoperative pain
- Complex regional pain syndrome
- HIV neuropathy
- Peripheral neuropathy
Exclusion
- Intravenous lidocaine and/or other treatment interfering with the protocol
Key Trial Info
Start Date :
March 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 28 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06171243
Start Date
March 17 2023
End Date
July 28 2025
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pontificia Universidad Catolica de Chile
Santiago, Santiago Metropolitan, Chile, 450881